<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-213" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Heart Transplantation Patient Selection</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brown</surname>
            <given-names>Kristen N.</given-names>
          </name>
          <aff>Augusta University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abraham</surname>
            <given-names>Joseph</given-names>
          </name>
          <aff>Unity Health-White County Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ashline</surname>
            <given-names>Peter T.</given-names>
          </name>
          <aff>University of Illinois Champaign, IL</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kanmanthareddy</surname>
            <given-names>Arun</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kristen Brown declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joseph Abraham declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peter Ashline declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arun Kanmanthareddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-213.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Heart failure (HF) is a major cause of morbidity and mortality in the United States and worldwide, and falls second only to pancreatic cancer as the pathology causing the shortest life expectancy. It plagues millions of people every year, and its frequency is only expected to continue rising. In the most advanced phase of heart failure, heart transplantation (HT) is the only means of improving the quality of life and survival. Unfortunately, not all patients who need a heart transplant meet criteria for receiving one. This activity describes the indications and contraindications for heart transplants and highlights the role of the interprofessional team in the management of heart failure patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for a heart transplant.</p></list-item><list-item><p>Describe the contraindications for a heart transplant.</p></list-item><list-item><p>Review the complications of a heart transplant.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients needing a heart transplant.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=213&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=213">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-213.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Heart failure (HF) is a major cause of morbidity and mortality in the United States and worldwide. It is only second to pancreatic cancer with the shortest life expectancy. It plagues millions of people every year. Currently, over 5 million people have an HF diagnosis, and that number is only expected to rise&#x000a0;in the future. Advanced heart failure or stage D disease affects &#x0003e;10% of&#x000a0;the heart failure&#x000a0;population.<xref ref-type="bibr" rid="article-213.r1">[1]</xref>&#x000a0;In the most advanced phase of heart failure, heart transplantation (HT) is the only means of improving the quality of life and survival in these patients. Unfortunately, not all patients who need a heart transplant meet criteria to receive a heart transplant. This chapter will cover in detail&#x000a0;patient selection for a heart transplant including indications, contraindications, medical professionals required to assess patient selection, preparation, and clinical significance.&#x000a0;</p>
      </sec>
      <sec id="article-213.s3" sec-type="Indications">
        <title>Indications</title>
        <p>There are several indications for a heart transplant. About 10-15% of patients currently&#x000a0;with heart failure meet requirements for a heart transplant (HT). However, less than half of these obtain a referral for transplant evaluation. Therefore, it is essential to spread awareness of indications for a heart transplant.&#x000a0;End-stage heart disease not amenable to other medical or surgical therapy is a class I indication for HT.<xref ref-type="bibr" rid="article-213.r2">[2]</xref>&#x000a0;End-stage heart failure is described as a left ventricular ejection fraction of less than 20% and peak&#x000a0;oxygen uptake of less than 12 mL/kg 1/min.&#x000a0;Cardiogenic shock, which requires either continuous intravenous inotropic support or mechanical circulatory support with an intra-aortic balloon pump counterpulsation device or LVAD, is also an indication&#x000a0;for HT. Other indications include anginal symptoms in the setting of&#x000a0;coronary artery disease not amenable to percutaneous or surgical revascularization or medical therapy and lethal arrhythmias resistant to medical therapy, catheter ablation, or implantation of an intracardiac defibrillator.<xref ref-type="bibr" rid="article-213.r3">[3]</xref></p>
      </sec>
      <sec id="article-213.s4" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Eligibility for a heart transplant&#x000a0;limited&#x000a0;as there are several contraindications to this procedure. Absolute contraindications include a life expectancy under two years despite a heart transplant.<xref ref-type="bibr" rid="article-213.r4">[4]</xref>&#x000a0;Some of the systemic illness that predict a life expectancy of less than two years include: acquired immunodeficiency syndrome with frequent&#x000a0;opportunistic infections, a significant pulmonary disease&#x000a0;usually identified with FEV less than 1 L/min, malignancy within the past five years, a current active systemic illness such as amyloidosis, sarcoidosis, or lupus, irreversible kidney disease, irreversible liver disease, fixed pulmonary hypertension as defined as pulmonary artery systolic pressure greater than 60 mmHg, mean transpulmonary gradient greater than 15 mmHg, or pulmonary vascular resistance greater than&#x000a0;6 Woods units.&#x000a0;<xref ref-type="bibr" rid="article-213.r5">[5]</xref><xref ref-type="bibr" rid="article-213.r6">[6]</xref></p>
        <p>There are several more relative contraindications.&#x000a0;Caution should be used in any patient presenting with any of the following characteristics: extremes in body mass index including morbid obesity and anorexia/cachexia, kidney dysfunction, liver dysfunction including international ratio (INR) &#x0003e; 1.5 off coumadin, bilirubinemia, active peptic ulcer disease, poorly controlled diabetes or hypertension, severe vascular disease including cerebrovascular or peripheral vascular disease, irreversible neurological disorder, irreversible neuromuscular disorder, heparin-induced thrombocytopenia (HIT) within 100 days, severe pulmonary disease with FEV1 less than 40% of normal, pulmonary infarct within last 2 months, active mental instability, and substance abuse including drugs, tobacco, or alcohol within the last 6 months.<xref ref-type="bibr" rid="article-213.r7">[7]</xref>&#x000a0;Age greater than 72 is also a known relative contraindication, however, according to literature, this is very controversial. One study showed that patients less than 40 years of age&#x000a0;had a 100% rate of long-term survival, and&#x000a0;lower&#x000a0;occurrence of complications.<xref ref-type="bibr" rid="article-213.r8">[8]</xref>&#x000a0;Another study showed no difference in outcome related to age using a personalized approach.<xref ref-type="bibr" rid="article-213.r9">[9]</xref></p>
      </sec>
      <sec id="article-213.s5" sec-type="Personnel">
        <title>Personnel</title>
        <p>The Heart Failure Team should include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primary cardiologist</p>
          </list-item>
          <list-item>
            <p>Advanced heart failure specialist</p>
          </list-item>
          <list-item>
            <p>Advanced heart failure nurse</p>
          </list-item>
          <list-item>
            <p>Cardiovascular pharmacist</p>
          </list-item>
          <list-item>
            <p>Cardiac rehabilitation specialist</p>
          </list-item>
          <list-item>
            <p>Palliative care nurse and specialist</p>
          </list-item>
          <list-item>
            <p>Clinical psychologist</p>
          </list-item>
          <list-item>
            <p>Clinical psychiatrist</p>
          </list-item>
          <list-item>
            <p>Primary care physician</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-213.s6" sec-type="Preparation">
        <title>Preparation</title>
        <p>The heart transplant (HT) process is complex and time-consuming. Preparing&#x000a0;a patient with advanced HF for a heart transplant starts first with identifying the current or future need for a transplant. This is by far the most crucial step in the whole process. Once identified, a speedy referral should&#x000a0;be placed to a&#x000a0;transplant center. Before the transplant appointment, it is imperative that the patient starts on goal-directed medical therapy (GDMT).<xref ref-type="bibr" rid="article-213.r1">[1]</xref> Patient ideally should be on GDMT for at least 3-6 months before&#x000a0;HT to assess therapeutic response.</p>
        <p>At the transplant center, an initial evaluation will be done to assess the severity of HF. Then an assessment for possible reversible factors will be made along with an assessment of the effectiveness of current medical therapy. Specific workup should be done on a patient's with valvular or ischemic heart disease. This subset should undergo an assessment with&#x000a0;myocardial viability testing&#x000a0;as well as&#x000a0;percutaneous transcatheter or surgical valve evaluation. Those with arrhythmias should be treated appropriately. For example, patients diagnosed with atrial fibrillation/flutter should be placed on rate controlling agents, and/or rhythm control with medication or cardioversion. Arrhythmia originating from the ventricular chambers should be treated with antiarrhythmic therapy, ablation, and/or implantable&#x000a0;defibrillator/pacemaker. Biventricular pacing should be considered for prolonged QRS.<xref ref-type="bibr" rid="article-213.r6">[6]</xref></p>
        <p>Patients should be instructed to refrain entirely from persistent alcohol intake, illicit drug use, or salt-retaining medications, as well as avoiding NSAIDs.<xref ref-type="bibr" rid="article-213.r10">[10]</xref>&#x000a0;One study found that there is no association between the presence of anxiety and depression and the outcome of heart transplantation.&#x000a0;<xref ref-type="bibr" rid="article-213.r3">[3]</xref>&#x000a0;However, many times patients are selected or not selected on this basis. Literature suggests that patients should not be withheld from HT with the presence of mild psychiatric illness. So regardless of the presence of anxiety or depression, if no reversible causes are diagnosed and the patient has been on several months of GDMT in the presence of&#x000a0;class IIIB/IV symptoms, then the transplant evaluation process will commence.</p>
        <p>If on referral the patient is in cardiogenic shock or on parenteral inotropic agents and cannot be tapered&#x000a0;because of hypotension, end-organ dysfunction, or symptoms, then the options for this patient are limited to cardiac transplantation, mechanical device support, or palliative care versus hospice. Evaluation of patients who are not inotrope dependent requires the collection of crucial prognostic factors to estimate patient prognosis and need for transplant listing. Also, one study found that there is no association between the presence of anxiety and depression and the outcome of heart transplantation.&#x000a0;<xref ref-type="bibr" rid="article-213.r3">[3]</xref>&#x000a0;However, many times patients are selected or not selected on this basis.&#x000a0;</p>
      </sec>
      <sec id="article-213.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Heart transplantation can prolong survival for up to 10 years or more.<xref ref-type="bibr" rid="article-213.r2">[2]</xref>&#x000a0;Having such a positive impact on survival makes the patient selection process for a&#x000a0;heart transplant an important focus in today heart failure talks.&#x000a0;Understanding the patient selection criteria for a heart transplant is crucial to clinical decision-making and making sure all patients indicated for&#x000a0;HT are captured and referred appropriately. It is imperative that physicians treating HF&#x000a0;(cardiologist and primary care) &#x000a0;to&#x000a0;be able to&#x000a0;recognize when a heart transplant is needed. Early identification is the key to a successful and speedy&#x000a0;heart transplant evaluation and list placement.</p>
      </sec>
      <sec id="article-213.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team that provides a patient-centered, integrated approach to evaluate patient's for&#x000a0;a heart transplant is essential to achieve the best possible outcomes. Furthermore, several studies have shown that the outcome of heart transplantation depends on several other factors outside of meeting clinical criteria such as demographic, psychosocial, and behavioral factors. It is imperative to have an interprofessional team including a cardiologist, thoracic surgeon, anesthetist, clinical psychologist and psychiatrist, pharmacists, and specialty trained nurses.<xref ref-type="bibr" rid="article-213.r11">[11]</xref>&#x000a0;[level 1] In particular, the nurses should assist the team with patient selection, education and monitoring; the clinicians should provide direct care and evaluation for the procedure; the pharmacist should assist in avoiding dangerous drug-drug interactions that may affect the outcome of the procedure; and the behavioralist should assist with helping the patient and family to cope with a challenging procedure fraut with potential complications and delays. [Level 5]</p>
      </sec>
      <sec id="article-213.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=213&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=213">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/213/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=213">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-213.s10">
        <fig id="article-213.image.f1" position="float" orientation="portrait">
          <caption>
            <p>The illustration shows the major signs and symptoms of heart failure. Contributed by National Heart, Lung, and Blood Institute, National Institutes of Health (NIH)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Heartfailure" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-213.s11">
        <fig id="article-213.image.f2" position="float" orientation="portrait">
          <caption>
            <p>NYHA Classification - Heart failure Contributed by the New York Health Association (NYHA)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NYHA__Classification" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-213.s12">
        <title>References</title>
        <ref id="article-213.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ural</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>&#x000c7;avu&#x0015f;o&#x0011f;lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Eren</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kara&#x000fc;z&#x000fc;m</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Temizhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Y&#x00131;lmaz</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Zoghi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ramassubu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of acute heart failure.</article-title>
            <source>Anatol J Cardiol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>860</fpage>
            <page-range>860-89</page-range>
            <pub-id pub-id-type="pmid">26574757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Munkholm-Larsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Heart transplantation.</article-title>
            <source>Ann Cardiothorac Surg</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>172</fpage>
            <pub-id pub-id-type="pmid">29492396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tecson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Felius</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Jamil</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Patient "Activation" of Patients Referred for Advanced Heart Failure Therapy.</article-title>
            <source>Am J Cardiol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>15</day>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>627</fpage>
            <page-range>627-631</page-range>
            <pub-id pub-id-type="pmid">30527769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirklin</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Terminal heart failure: who should be transplanted and who should have mechanical circulatory support?</article-title>
            <source>Curr Opin Organ Transplant</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>486</fpage>
            <page-range>486-93</page-range>
            <pub-id pub-id-type="pmid">25186823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freeman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koerner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halabicky</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Path From Heart Failure to Cardiac Transplant.</article-title>
            <source>Crit Care Nurs Q</source>
            <year>2016</year>
            <season>Jul-Sep</season>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-13</page-range>
            <pub-id pub-id-type="pmid">27254637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Correia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Batista</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Results of heart transplantation in the urgent recipient--who should be transplanted?</article-title>
            <source>Rev Bras Cir Cardiovasc</source>
            <year>2014</year>
            <season>Jul-Sep</season>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>379</fpage>
            <page-range>379-87</page-range>
            <pub-id pub-id-type="pmid">25372913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cimato</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Recipient selection in cardiac transplantation: contraindications and risk factors for mortality.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>11</issue>
            <fpage>1161</fpage>
            <page-range>1161-73</page-range>
            <pub-id pub-id-type="pmid">12431490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prieto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Correia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Batista</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>Mde J</given-names>
              </name>
            </person-group>
            <article-title>Heart Transplantation in Patients Older than 65 Years: Worthwhile or Wastage of Organs?</article-title>
            <source>Thorac Cardiovasc Surg</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>684</fpage>
            <page-range>684-91</page-range>
            <pub-id pub-id-type="pmid">25415627</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sponga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deroma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sappa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Piani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lechiancole</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spagna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tursi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nalli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Livi</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Recipient age impact on outcome after cardiac transplantation: should it still be considered in organ allocation?</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>573</fpage>
            <page-range>573-9</page-range>
            <pub-id pub-id-type="pmid">27316658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalter-Leibovici</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Freimark</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ziv</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Benderly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cukierman-Yaffe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asher</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Grupper</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amitai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Matetzky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>H</given-names>
              </name>
              <collab>Israel Heart Failure Disease Management Study (IHF-DMS) investigators</collab>
            </person-group>
            <article-title>Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial.</article-title>
            <source>BMC Med</source>
            <year>2017</year>
            <month>May</month>
            <day>01</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <pub-id pub-id-type="pmid">28457231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farmer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Grady</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Cotts</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Demographic, psychosocial, and behavioral factors associated with survival after heart transplantation.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>876</fpage>
            <page-range>876-83</page-range>
            <pub-id pub-id-type="pmid">23374446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-213.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bart</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Understanding Tricuspid Regurgitation Post Cardiac Transplantation; Why "Anatomical" and "Functional" Just Won't Cut It.</article-title>
            <source>Transplantation</source>
            <year>2024</year>
            <month>Mar</month>
            <day>01</day>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>662</fpage>
            <page-range>662-668</page-range>
            <pub-id pub-id-type="pmid">37578343</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
